STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Stoke Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$24.82+0.65 (+2.69%)
Close on Oct 19, 2026
- Market cap
- $1.64B
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Stoke Therapeutics has not reported a dividend
No dividend per share appears in Stoke Therapeutics's annual filings since fiscal 2017.